Get cannabis company insight and analysis from an experienced stock trading pro with a 35 year memory of market booms and busts, with access to an extensive cannabis industry contact network in North America. Chris Damas is an analyst sought after by institutional hedge funds for his insight into the stock market – widely quoted in the media on the agriculture and fertilizer industry since 2007. Chris is an ex-securities industry compliance executive and is completely unafraid to unmask stock promotions in the cannabis space, helping investors pick winners and avoid losers.

Basic Subscription

$2495 /Month

($24900 anually)

  • Access to Members' section and BCMI Cannabis Report Archive
  • The BCMI Cannabis Report delivered directly to your email inbox
  • BCMI Flash Content - Regular timely insights from Chris, delivered via email
Get the Report

Premium Subscription

$9995 /Month

($99900 anually)

  • Access to Members' section and BCMI Cannabis Report Archive for up to 4 users
  • The BCMI Cannabis Report delivered to all users' email inboxes
  • BCMI Flash Content - Regular timely insights from Chris, delivered via email
  • 30 minutes of strategic advice time per quarter directly from Chris on the subject of your choosing
  • Proprietary cannabis stock spreadsheet information upon request
Get the Report

* Corporations and industry professionals are required to subscribe to our Premium service.

Selected Videos

screen shot from bnn
china_dec30
Cannabis Stocks
Agrium-Potash
“For over two years, I have advised investors to prefer what I call the “Big Four” cannabis licensed producers over smaller companies, before this term became fashionable. I correctly predicted that medical cannabis names such as CanniMed and MedReleaf would be most attractive to bigger players.”
~ Chris Damas, speaking to institutional investors MJBizCon, Las Vegas, November 13, 2018

As Published On

tipranks logo
seeking alpha logo
BNN Logo
Vice logo
Marijuana Business Daily logo